Swiss Insurance Association

Recent papers from Swiss Insurance Association

1. Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data.2025
2. Emission-Responsive Charging of Electric Cars and Carsharing to Improve the Security of Electricity Supply for SwitzerlandEnvironmental Science & Technology · 2025
3. Blood-Borne Infection Prevention in Combat Sports: Position Statement of the Association of Ringside PhysiciansClinical Journal of Sport Medicine · 2025
4. Towards Diagnosing and Mitigating Behavioral Cyber RisksRisks · 2024
5. Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAPEFLM PaperDiagnostyka Laboratoryjna · 2024
6. Escalating to medium‐ versus high‐efficacy disease modifying therapy after low‐efficacy treatment in relapsing remitting multiple sclerosisBrain and Behavior · 2024
7. Comparative analysis of dimethyl fumarate and teriflunomide in relapsing–remitting multiple sclerosisEuropean Journal of Neurology · 2023
8. Detection of antinuclear antibodies: recommendations from EFLM, EASI and ICAPClinical Chemistry and Laboratory Medicine (CCLM) · 2023
9. Genomic regions underlying positive selection in local, Alpine cattle breedsAnimal Genetics · 2023
10. Mental health challenges and digital platform opportunities in patients and families affected by pediatric neuromuscular diseases - experiences from SwitzerlandDigital Health · 2023
11. Likelihood Ratio Approach and Clinical Interpretation of Laboratory TestsFrontiers in Immunology · 2021
12. Harmonization of antineutrophil cytoplasmic antibodies (ANCA) testing by reporting test result-specific likelihood ratios: position paperClinical Chemistry and Laboratory Medicine (CCLM) · 2020
13. Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosisJournal of Neurology · 2020
14. Likelihood Ratios as Value Proposition for Diagnostic Laboratory TestsThe Journal of Applied Laboratory Medicine · 2020
15. Results from an Epidemiological Follow-Up Survey on Home Artificial Nutrition in Switzerland from 2010 to 2015Annals of Nutrition and Metabolism · 2020
16. Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosisMultiple Sclerosis Journal · 2018
17. Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and PatientsRheumatology and Therapy · 2017
18. Aged embankment imaging and assessment using surface wavesProceedings of the Institution of Civil Engineers - Forensic Engineering · 2016
19. Grasping intersubjectivity: an invitation to embody social interaction researchPhenomenology and the Cognitive Sciences · 2016
20. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemiaLeukemia & lymphoma/Leukemia and lymphoma · 2015